Glucocorticoid-Induced Osteoporosis

Osteoporosis, Two-Volume Set

Volumn , Issue , 2008, Pages 1135-1166

  Adler, Robert A ^a   Curtis, Jeffrey ^b   Weinstein, Robert S ^c,d   Saag, Kenneth G ^e  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The University of Alabama at Birmingham   (United States)

^c Center for Osteoporosis and Metabolic Bone Diseases   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73649122035     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370544-0.50046-X     Document Type: Chapter

References (297)

1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932, 50:137-195.
2. Canalis E., Bilezikian J.P., Angeli A., Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004, 34:593-598.
3. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
4. van Staa T., Leufkens H., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
5. Hench P.S., Kendall E.C., Slocumb C.H., et al. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med 1950, 85:545-666.
6. Dykman T.R., Gluck O.S., Murphy W.A., Hahn T.J., Hahn B.H. Evaluation of factors associated with glucocorticoid- induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985, 28:361-368.
7. Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990, 112:352-364.
8. Sambrook P.N., Jones G. Corticosteroid osteoporosis. Br J Rheumatol 1995, 34:8-12.
9. Walsh L.J., Wong C.A., Pringle M., Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. Br Med J 1996, 313:344-346.
10. Mudano A., Allison J., Hill J., Rothermal T., Saag K. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 2001, 28:1298-1305.
11. Chantler I.W., Davie M.W., Evans S.F., Rees J.S. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 2003, 62:350-352.
12. Verstraeten A., Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: Effect of low dose corticosteroids. Ann Rheum Dis 1986, 45:852-857.
13. Reid I.R., Evans M.C., Wattie D.J., et al. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid- treated asthmatic patients. Osteoporosis Int 1992, 2:103-105.
14. LoCascio V., Bonnucci E., Imbimbo B., Ballanti P., Adami S., Milani S., Tartarotti D., DellaRocca C. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990, 8:39-51.
15. Laan R.F.J.M., Buijs W.C.A.M., van Erning L.J.T., Lemmens J.A.M., Corstens F.H.M., Ruijs S.H.J., van de Putte L.B.A., van Riel P.L.C.M. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 1993, 52:5-9.
16. Sambrook P.N., Eisman J.A., Yeates M.G., et al. Osteoporosis in rheumatoid arthritis: Safety of low dose corticosteroids. Ann Rheum Dis 1986, 45:950-953.
17. Messina O.D., Barreira J.C., Zanchetta J.R., Maldonado- Cocca J.A., Bogado C.E., Sebastian O.N., et al. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992, 19:1520-1526.
18. Hall G.M., Spector T.D., Griffin J.A., Jawad A.S.M., Hall M.L., Doyle D.V. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993, 36:1510-1516.
19. Kroger H., Honaken R., Saarikoski S., Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis-A population based study. Ann Rheum Dis 1994, 53:18-23.
20. Lane N.E., Pressman A.R., Star V.L., Cummings S.R., Nevitt M.C. Rheumatoid arthritis and bone mineral density in elderly women. J Bone Miner Res 1995, 10:257-263.
21. Garton M.J., Reid D.M. Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids. Arthritis Rheum 1993, 36:222-228.
22. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., Cooper S.M. Effects of low dose glucocorticoids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995, 22:1055-1059.
23. Reid I.R., Heap S.W. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990, 150:2545-2548.
24. Emkey R.D., Lindsay R., Lyssy J., et al. The systemic effect of intraarticular administration of corticosteroid on markers on bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:277-282.
25. Toogood J.H., Hodsman A.B., Fraher L.J., Markov A.E., Baskerville J.C. Serum osteocalcin and procollagen as markers for the risk of osteoporotic fracture in corticosteroidtreated asthmatic adults. J Allergy Clin Immunol 1999, 104:769-774.
26. Ton F.N., Gunawardene S.C., Lee H., Neer R.M. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005, 20:464-470.
27. Saito J.K., Davis J.W., Wasnich R.D., et al. Users of lowdose glucocorticoids have increased bone loss rates: A longitudinal study. Calcif Tissue Int 1995, 57:115-119.
28. Pearce G., Tabensky A., Delmas P.D., Gordon Baker H.W., Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998, 83:801-806.
29. McEvoy C.E., Ensrud K.E., Bender E., Genant H.K., Yu W., Griffith J.M., Niewoehner D.E. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:704-709.
30. Als O.S., Gotfredsen A., Christiansen C. The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Arthritis Rheum 1985, 28:369-375.
31. Ramsey-Goldman R., Dunn J.E., Huang C.-F., Dunlop D., Rairie J.E., Fitzgerald S., Manzi S. Frequency of fractures in women with systemic lupus erythematosus: Comparison with United States population data. Arthritis Rheum 1999, 42:882-890.
32. Zonana-Nacach A., Barr S.G., Magder L.S., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43:1801-1808.
33. van Staa T.P., Geusens P., Bijlsma J.W., Leufkens H.G., Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3104-3112.
34. van Staa T.P., Geusens P., Pols H.A., de Laet C., Leufkens H.G., Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005, 98:191-198.
35. Peel N.F.A., Moore D.J., Barrington N.A., Bax D.E., Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995, 54:801-806.
36. Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 2005, 3:98-102.
37. Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983, 309:265-268.
38. Saag K.G., Emkey R., Schnitzer T., et al. Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292-299.
39. Cohen S., Levy R.M., Keller M., Boling E., Emkey R.D., Greenwald M., Zizic T.M., Wallach S., Sewell K.L., Lukert B.P., Axelrod D.W., Chines A.A. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318.
40. Luengo M., Picado C., Del Rio L., Guanabens N., Montserrat J.M., Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: A comparative study. Thorax 1991, 46:803-806.
41. van Staa T.P., Laan R.F., Barton I.P., Cohen S., Reid D.M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
42. Kanis J.A., Johansen H.K., Oden A., Johnell O., De Laet C., Melton L.J., Tenenhouse A., Reeve J., Silman A.J., Pols H.A.P., Eisman J.A., McCloskey E.V., Mellstrom D. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893-899.
43. Evans S.F., Davie M.W.J. Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men. Ann Rheum Dis 2000, 59:269-275.
44. Naganathan V., Jones G., Nash P., Nicholson G., Eisman J., Sambrook P.N. Vertebral fracture risk with long-term corticosteroid therapy. Arch Int Med 2000, 160:2917-2922.
45. Selby P.L., Halsey J.P., Adams K.R.H., Klimiuk P., Knight S.M., Pal B., Stewart I.M., Swinson D.R. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 2000, 15:952-956.
46. van Staa T.P., Leukens H.G.M., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383-1389.
47. Godschalk M.F., Downs R.W. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988, 3:113-115.
48. Nielsen H.K., Charles P., Mosekilde L. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab 1988, 67:1025-1030.
49. van Staa T., Leufkens H., Cooper C. The epidemiology of corticosteroid induced osteoporosis: A meta-analysis. Osteoporos Int 2002, 13:777-787.
50. Steinbuch M., Youket T.E., Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004, 15:323-328.
51. Gluck O.S., Murphy W.A., Hahn T.J., et al. Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum 1981, 24:892-898.
52. Haugeberg G., Griffiths B., Sokoll K.B., Emery P. Bone loss in patients treated with pulses of methylprednisolone is not negligible: A short term prospective observational study. Ann Rheum Dis 2004, 63:940-944.
53. Vestergaard P., Olsen M.L., Paaske Johnsen S., Rejnmark L., Sorensen H.T., Mosekilde L. Corticosteroid use and risk of hip fracture: A population-based case-control study in Denmark. J Intern Med 2003, 254:486-493.
54. Adler R.A., Hochberg M.C. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003, 163:2619-2624.
55. Haugeberg G., Uhlig T., Falch J.A., Halse J.I., Kvien T.K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:522-530.
56. de Nijs R.N.J., Jacobs J.W.G., Gijlsma J.W.J., Lems W.F., Laan R.F.J.M., Houben H.H.M., ter Borg E.J., Huisman A.M., Bruyn G.A.W., van Oijen P.L.M., Westgeest A.A.A., Algra A., Hofman on behalf of the Osteoporosis Working Group of the Dutch Society for Rheumatology D.M. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 2001, 40:1375-1383.
57. Haugeberg G., Orstavik R., Uhlig T., Falch J.A., Halse J.I., Kvien T.K. Bone loss in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1720-1728.
58. Michel B.A., Bloch D.A., Wolfe F., Fries J. Fractures in rheumatoid arthritis: An evaluation of associated risk factors. J Rheum 1993, 20:1666-1669.
59. Saag K.G., Koehnke R., Caldwell J.R., Brasington R., Burmeister L.F., Zimmerman B., Kohler J.A., Furst D.E. Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med 1994, 96:115-123.
60. Lems W.F., Jahangier Z.N., Jacobs J.W.G., Bijlsma J.W.J. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995, 13:293-297.
61. McDougall R., Sibley J., Haga M., Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheum 1994, 21:1207-1213.
62. Hansen M., Podenphant J., Florescu A., Stoltenberg M., Borch A., Kluger E., Freiesleben Sorensen S., Mork Hansen T. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis 1999, 58:713-718.
63. Orstavik R.E., Haugeberg G., Uhlig T., Mowinckel P., Falch J.A., Halse J.I., Kvien T.K. Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: Incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis 2004, 63:177-182.
64. Bijlsma J.W.J., Saag K.G., Buttgereit F., da Silva J.A.P. Developments in glucocorticoid therapy. Rheum Dis Clin North Am 2005, 31:1-17.
65. Gough K.S., Lilley J., Eyre S., Holder R.L., Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23-27.
66. Towheed T.E., Brouillard D., Yendt E., Anastassiades T. Osteoporosis in rheumatoid arthritis: Findings in the metacarpal, spine, and hip and a study of the determinants of both localized and generalized osteopenia. J Rheumatol 1995, 22:440-443.
67. Hansen M., Florescu A., Stoltenberg M., Podenphant J., Pedersen-Zbinden B., Horsley-Petersen K., Hyldstrup L., Lorenzen I. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. Scand J Rheumatol 1996, 25:367-376.
68. Suzuki Y., Mizushima Y. Osteoporosis in rheumatoid arthritis. Osteoporosis Int 1997, 7(Suppl.):S217-S222.
69. Gough A., Sambrook P., Devlin J., Huissoon A., Njeh C., Robbins S., Nguyen T., Emery P. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998, 25:1282-1289.
70. Spector T.D., Hall G.M., McCloskey E.V., Kanis J.A. Risk of vertebral fracture in women with rheumatoid arthritis. Br Med J 1993, 306:558.
71. Cooper C., Coupland C., Mitchell M. Rheumatoid arthritis corticosteroid therapy and hip fracture. Ann Rheum Dis 1995, 54:49-52.
72. Baltzan M.A., Suissa S., Bauer D.C., Cummings S.R. Hip fractures attributable to corticosteroid use. Lancet 1999, 353:1327.
73. Haugeberg G., Ørstavik R.E., Kvien T.K. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003, 15:469-475.
74. Orstavik R.E., Mowinckel P., Hoiseth A., Uhlig T., Falch J.A., Halse J.I., McCloskey E., Kvien T.K. Vertebral deformities in rheumatoid arthritis: A comparison with population- based controls. Arch Int Med 2004, 164:420-425.
75. Sambrook P.N., Eisman J., Champion G.D., Yeates M.G., Pocock N.A., Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 1987, 30:721-728.
76. Sambrook P.N., Cohen M.L., Eisman J.A., Pocock N.A., Champion G.D., Yeates M.G. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: A longitudinal study. Ann Rheum Dis 1989, 48:535-538.
77. Leboff M.S., Wade J.P., Mackowiak S., Ful G.E.-H., Zangari M., Liang M.H. Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. J Rheumatol 1991, 18:339-344.
78. Lodder M.C., Lems W.F., Kostense P.J., Verhoeven A.C., Dijkmans B.A., Boers M. Bone loss due to glucocorticoids: Update of a systematic review of prospective studies in rheumatoid arthritis and other diseases. Ann Rheum Dis 2003, 62:94.
79. Sambrook P.N., Hughes D.R., Nelson A.E., Robinson B.G., Mason R.S. Osteocyte viability with glucocorticoid treatment: Relation to histomorphometry. Ann Rheum Dis 2003, 62:1215-1217.
80. Verhoeven A.C., Boers M. Limited bone loss due to corticosteroids: A systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997, 24:1495-1503.
81. Kirwan J.R. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med, 1995, 333:142-146.
82. van Everdingen A.A., Jacobs J.W.G., van Reesema D.R., Bijlsma J.W.J. Low dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease modifying properties and side effects. A double-blind placebo-controlled clinical trial. Ann Intern Med 2002, 136:1-12.
83. Cappell H.A., Madhok R., Hunter J.A., Porter D., Morrison E., Larkin J., Thomson E.A., Hampson R., Poon F.W. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial. Ann Rheum Dis 2004, 63:797-803. on behalf of the WOSERACT Group.
84. Svensson B., Boonen A., Albertsson K., van der Heijde D., Keller C., Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005, 52:3360-3370. for the BARFOT Study Group.
85. Wassenberg S., Rau R., Steinfeld P., Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double-blind, placebo- controlled trial. Arthritis Rheum 2005, 52:3371-3380. for the Low-Dose Prednisolone Therapy Study Group.
86. Bijlsma J.W., Boers M., Saag K.G., Furst D.E. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003, 62:1033-1037.
87. Da Silva J.A., Jacobs J.W., Kirwan J.R., Boers M., Saag K.G., Ines L.B., de Koning E.J., Buttgereit F., Cutolo M., Capell H., Rau R., Bijlsma J.W. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006, 65:285-293.
88. Dolan A.L., Moniz C., Dasgupta B., Li F., Mackintosh C., Todd P., Corrigall V., Panayi G.S. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997, 40:2022-2029.
89. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., Hunder G.G. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Rheum 1997, 49:703-708.
90. Gilboe I.M., Kvien T.K., Haugeberg G., Husby G. Bone mineral density in systemic lupus erythematosus: Comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis 2000, 59:110-115.
91. Kipen Y., Buchbinder R., Forbes A., Strauss B., Littlejohn G., Morand E. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol 1997, 24:1922-1929.
92. Sinigaglia L., Varenna M., Binelli L., Zucchi F., Ghiringhella D., Gallazzi M., Limonta M., Zeni S., Fantini F. Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on premenopausal women. J Rheumatol 1999, 26:1280-1284.
93. Yee C.S., Crabtree N., Skan J., Amft N., Bowman S., Situnayake D., Gordon C. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:111-113.
94. Gluck O., Colice G. Recognizing and treating glucocorticoid- induced osteoporosis in patients with pulmonary diseases. Chest 2004, 125:1859-1876.
95. van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001, 16:581-588.
96. Teelucksingh S., Padfield P.L., Tibi L., Gough K.J., Holt P.R. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 1991, 338:60-61.
97. Marystone J.F., Barrett-Connor E.L., Morton D.J. Inhaled and oral corticosteroids: Their effects on bone mineral density in older adults. Am J Public Health 1995, 85:1693-1695.
98. Toogood J.H., Baskerville J.C., Markov A.E., Hodsman A.B., Fraher L.J., Jennings B., Haddad R.G., Drost D. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995, 96:157-166.
99. Wong C.A., Walsh L.J., Smith C.J.P., Wisniewski A.F., Lewis S.A., Hubbard R., Dawte S., Green D.J., Pringle M., Tattersfield A.E. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000, 355:1399-1403.
100. Israel E., Banerjee T.R., Fitzmaurice G.M., Kotlov T.V., LaHive K., LeBoff M.S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001, 345:941-947.
101. Scanlon P.D., Connett J.E., Wise R.A., Tashkin D.P., Madhok T., Skeans M., Carpenter P.C., Bailey W.C., Buist A.S., Eichenhorn M., Kanner R.E., Weinmann G. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004, 170:1302-1309.
102. Fujita K., Kasayama S., Hashimoto J., Nagasaka Y., Nakano N., Morimoto Y., Barnes P.J., Miyatake A. Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women. J Bone Miner Res 2001, 16:782-787.
103. Hubbard R.B., Smith C.J., Smeeth L., Harrison T.W., Tattersfield A.E. Inhaled corticosteroids and hip fracture: A population-based case-control study. Am J Respir Crit Care Med 2002, 166:1563-1566.
104. Campbell I.A., Douglas J.G., Francis R.M., Prescott R.J., Reid D.M. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 2004, 59:761-768.
105. Israel E., Banerjee T.R., Fitzmaurice G.M., Kotlov T.V., LaHive K., LeBoff M.S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001, 345:941-947.
106. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999, 159:941-955.
107. Jones A., Fay J.K., Burr M., et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002, CD003537.
108. Suissa S., Baltzan M., Kremer R., Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004, 169:83-88.
109. de Vries F., van Staa T.P., Bracke M.S., Cooper C., Leufkens H.G., Lammers J.W. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005, 25:879-884.
110. Bernstein C.N., Blanchard J.F., Leslie W., Wajda A., Yu B.N. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000, 133:795-799.
111. Vestergaard P., Krogh K., Rejnmark L., Laurberg S., Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000, 46:176-181.
112. Vestergaard P., Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: A nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1-10.
113. Andreassen H., Hylander E., Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: A case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999, 94:824-828.
114. Schoon E.J., Bollani S., Mills P.R., Israeli E., Felsenberg D., Ljunghall S., Persson T., Hapten-White L., Graffner H., Bianchi Porro G., Vatn M., Stockbrugger R.W. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3:113-121.
115. Robinson R.J., Iqbal S.J., Wolfe R., Patel K., Abrams K., Mayberry J.F. The effect of rectally administered steroids on bone turnover: A comparative study. Aliment Pharmacol Ther 1998, 12:213-217.
116. Young C.A., Williams I.R., MacFarlane I.A. Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate. Br J Clin Pract 1991, 45:61-62.
117. Summey B.T., Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: An update. Arch Dermatol 2006, 142:82-90.
118. Buckley L.M., Marquez M., Feezor R., Ruffin D.M., Benson L.L. Prevention of corticosteroid-induced osteoporosis: Results of a patient survey. Arthritis Rheum 1999, 42:1736-1739.
119. Gudbjornsson B., Juliusson U.I., Gudjonsson F.V. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002, 61:32-36.
120. Solomon D.H., Katz J., Jacobs J.W., La Tourette A., Coblyn J. Management of glucocorticoid induced osteoporosis in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:3136-3142.
121. Ramsey-Goldman R. Missed opportunities in physician management of glucocorticoid-induced osteoporosis?. Arthritis Rheum. 2002, 46:3115-3120.
122. Curtis J.R., Westfall A.O., Allison J., Bijlsma J.W., Freeman A., George V., Kovac S.H., Spettell C.M., Saag K.G. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006, 55:420-426.
123. Saag K.G., Gehlbach S.H., Curtis J.R., Youket T.E., Worley K., Lange J.L. Trends in prevention of glucocorticoid- induced osteoporosis. J Rheumatol 2006, 33:1651-1657.
124. Osiri M., Saag K.G., Ford A.M., Moreland L.W. Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. J Clin Rheumatol 2000, 6:117-122.
125. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001, 44:1496-1503. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
126. Rosen H.N., Rosenblatt M. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate 2003, 11. UpToDate, Wellesley, MA, , No. 1. B. Rose (Ed.).
127. Buckley L.M., Marquez M., Hudson J.O., Downs R.W., Vacek P., Small R.E., Poses R. Variations in physician perceptions of the risk of osteoporosis in corticosteroid users by physician specialty. J Rheumatol 1998, 25:2195-2202.
128. Blalock S.J., Norton L.L., Patel R.A., Dooley M.A. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2005, 53:732-739.
129. Liu R.H., Albrecht J., Werth V.P. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 2006, 142:37-41.
130. Naunton M., Peterson G.M., Jones G., Griffin G.M., Bleasel M.D. Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 2004, 31:550-556.
131. Solomon D.H., Katz J.N., La Tourette A.M., Coblyn J.S. Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: A randomized controlled trial. Arthritis Rheum 2004, 51:383-387.
132. McDonough R.P., Doucette W.R., Kumbera P., Klepser D.G. An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health 2005, 8:24-31.
133. Kiefe C.I., Allison J.J., Williams O.D., Person S.D., Weaver M.T., Weissman N.W. Improving quality improvement using achievable benchmarks for physician feedback: A randomized controlled trial. JAMA 2001, 285:2871-2879.
134. J. R. Curtis, A. O. Westfall, J. J. Allison, A. Becker, M. MacArthur, T. Ockershausen, E. Stewart, N. W. Weissman, K. G. Saag: Challenges in improving the quality of osteoporosis care for long term glucocorticoid users: A prospective, randomized trial. Arch Intern Med, 167, 591-596.
135. O'Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., Stewart S.A., Manolagas S.C., Weinstein R.S. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145:1835-1841.
136. Jia D., O'Brien C.A., Stewart S.A., Manolagas S.C., Weinstein R.S. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006, 147:5592-5599.
137. Baccan G.C., Oliveira R.D., Mantovani B. Stress and immunological phagocytosis: Possible nongenomic action of corticosterone. Life Sci 2004, 75:1357-1368.
138. Falkenstein E., Tillmann H.C., Christ M., Feuring M., Wehling M. Multiple actions of steroid hormones-A focus on rapid, nongenomic effects. Pharmacol Rev 2000, 52:513-556.
139. Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., Gass P., Schmid W., Herrlich P., Angel P., Schutz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998, 93:531-541.
140. Williams G.H. Guardian of the gate: Receptors, enzymes, and mineralocorticoid function. J Clin Endocrinol Metab 1992, 74:961-962.
141. Weinstein R.S. 11β-HSD: Guardian or gate crasher?. BoneKEy- OsteoVision 2005, 2:6-13.
142. Chappard D., Legrand E., Basle M.F., Fromont P., Racineux J.L., Rebel A., Audran M. Altered trabecular architecture induced by corticosteroids: A bone histomorphometric study. J Bone Miner Res 1996, 11:676-685.
143. Dempster D.W. Bone histomorphometry in glucocorticoidinduced osteoporosis. J Bone Miner Res 1989, 4:137-141.
144. Dempster D.W., Arlot M.A., Meunier P.J. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983, 35:410-417.
145. Vedi S., Elkin S.L., Compston J.E. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif Tissue Int 2005, 77:79-83.
146. Weinstein R.S. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001, 2:65-73.
147. Weinstein R.S., Jia D., Powers C.C., Stewart S.A., Jilka R.L., Parfitt A.M., Manolagas S.C. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 2004, 145:1980-1987.
148. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282.
149. Valero M.A., Leon M., Ruiz Valdepenas M.P., Larrodera L., Lopez M.B., Papapietro K., Jara A., Hawkins F. Bone density and turnover in Addison's disease: Effect of glucocorticoid treatment. Bone Miner 1994, 26:9-17.
150. Zelissen P.M., Croughs R.J., van Rijk P.P., Raymakers J.A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994, 120:207-210.
151. Weinstein R.S., Chen J.R., Powers C.C., Stewart S.A., Landes R.D., Bellido T., Jilka R.L., Parfitt A.M., Manolagas S.C. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002, 109:1041-1048.
152. Ohnaka K., Taniguchi H., Kawate H., Nawata H., Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: Novel mechanism of glucocorticoid- induced osteoporosis. Biochem Biophys Res Commun 2004, 318:259-264.
153. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C., Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389.
154. Vidal N.O., Brandstrom H., Jonsson K.B., Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids. J Endocrinol 1998, 159:191-195.
155. Khosla S., Melton L.J., Atkinson E.J., O'Fallon W.M., Klee G.G., Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83:2266-2274.
156. Fink H.A., Ewing S.K., Ensrud K.E., Barrett-Connor E., Taylor B.C., Cauley J.A., Orwoll E.S. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006, 91:3908-3915.
157. Stanczyk F.Z., Petra P.H., Senner J.W., Novy M.J. Effect of dexamethasone treatment on sex steroid-binding protein, corticosteroid-binding globulin, and steroid hormones in cycling rhesus macaques. Am J Obstet Gynecol 1985, 151:464-470.
158. Montecucco C., Caporali R., Caprotti P., Caprotti M., Notario A. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol 1992, 19:1895-1900.
159. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102(8):1627-1633.
160. Reid I.R., Wattie D.J., Evans M.C., Stapleton J.P. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996, 156:1173-1177.
161. Crawford B.A., Liu P.Y., Kean M.T., Bleasel J.F., Handelsman D.J. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003, 88:3167-3176.
162. Kream B.E., Lukert B.P. Clinical and basic aspects of glucocorticoid action in bone. Principles Bone Biol 2002, 1:723-740.
163. European Renal Association-European Dialysis and Transplantation Association, IV. Section 10: Pregnancy in renal transplant recipients:
164. Rizzoni G., Ehrich J.H., Broyer M., Brunner F.P., Brynger H., Fassbinder W., Geerlings W., Selwood N.H., Tufveson G., Wing A.J. Successful pregnancies in women on renal replacement therapy: Report from the EDTA Registry. Nephrol Dial Transplant 1992, 7:279-287.
165. Tauchmanova L., Pivonello R., Di Somma C., Rossi R., De Martino M.C., Camera L., Klain M., Salvatore M., Lombardi G., Colao A. Bone demineralization and vertebral fractures in endogenous cortisol excess: Role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006, 91:1779-1784.
166. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Endocrinology 1997, 138:4013-4021.
167. Bellows C.G., Aubin J.E., Heersche J.N. Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro. Endocrinology 1987, 121:1985-1992.
168. Klein R.G., Arnaud S.B., Gallagher J.C., Deluca H.F., Riggs B.L. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977, 60:253-259.
169. Vieth R. What is the optimal vitamin D status for health?. Prog Biophys Mol Biol 2006, 92:26-32.
170. Cosman F., Nieves J., Herbert J., Shen V., Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994, 9:1097-1105.
171. Adler R.A., Funkhouser H.L., Petkov V.I., Berger M.M. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 2003, 325:1-6.
172. Suzuki Y., Ichikawa Y., Saito E., Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983, 32:151-156.
173. Rubin M.R., Bilezikian J.P. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid- induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab 2002, 87:4033-4041.
174. Bonadonna S., Burattin A., Nuzzo M., Bugari G., Rosei E.A., Valle D., Iori N., Bilezikian J.P., Veldhuis J.D., Giustina A. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 2005, 152:199-205.
175. Koo K.H., Kim R., Kim Y.S., Ahn I.O., Cho S.H., Song H.R., Park Y.S., Kim H., Wang G.J. Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol 2002, 21:299-303.
176. Mankin H.J. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992, 326:1473-1479.
177. Marston S.B., Gillingham K., Bailey R.F., Cheng E.Y. Osteonecrosis of the femoral head after solid organ transplantation: A prospective study. J Bone Joint Surg Am 2002, 84-A:2145-2151.
178. Weinstein R.S., Nicholas R.W., Manolagas S.C. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000, 85:2907-2912.
179. Exton J.H. Regulation of gluconeogenesis by glucocorticoids. Monogr Endocrinol 1979, 12:535-546.
180. Horinouchi H., Kumamoto T., Kimura N., Ueyama H., Tsuda T. Myosin loss in denervated rat soleus muscle after dexamethasone treatment. Pathobiology 2005, 72:108-116.
181. Nordsborg N., Goodmann C., McKenna M.J., Bangsbo J. Dexamethasone up-regulates skeletal muscle maximal Na+,K+ pump activity by muscle group specific mechanisms in humans. J Physiol 2005, 567:583-589.
182. Schotanus B.A., Meij B.P., Vos I.H., Kooistra H.S., Everts M.E. Na(+), K(+)-ATPase content in skeletal muscle of dogs with pituitary-dependent hyperadrenocorticism. Domest Anim Endocrinol 2006, 30:320-332.
183. Konno S. Hydroxyl radical formation in skeletal muscle of rats with glucocorticoid-induced myopathy. Neurochem Res 2005, 30:669-675.
184. Lee M.C., Wee G.R., Kim J.H. Apoptosis of skeletal muscle on steroid-induced myopathy in rats. J Nutr 2005, 135:1806S-1808S.
185. Natsui K., Tanaka K., Suda M., Yasoda A., Sakuma Y., Ozasa A., Ozaki S., Nakao K. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006, 17:105-108.
186. Braith R.W., Magyari P.M., Pierce G.L., Edwards D.G., Hill J.A., White L.J., Aranda J.M. Effect of resistance exercise on skeletal muscle myopathy in heart transplant recipients. Am J Cardiol 2005, 95:1192-1198.
187. Kirwan J.R., Russell A.S. Systemic glucocorticoid treatment in rheumatoid arthritis-A debate. Scand J Rheumatol 1998, 27:247-251.
188. de Nijs R.N., Jacobs J.W., Lems W.F., Laan R.F., Algra A., Huisman A.M., Buskens E., de Laet C.E., Oostveen A.C., Geusens P.P., Bruyn G.A., Dijkmans B.A., Bijlsma J.W. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006, 355:675-684.
189. Pocock N.A., Eisman J.A., Dunstan C.R., et al. Recovery from steroid-induced osteoporosis. Ann Intern Med 1987, 107:319.
190. Adachi J.D., Olszynski W.P., Hanley D.A., Hodsman A.B., Kendler D.L., Siminoski K.G., Brown J., Cowden E.A., Goltzman D., Ioannidis G., Josse R.G., Ste-Marie L.-G., Tenenhouse A.M., Davison K.S., Blocka K.L.N., Pollock A.P., Sibley J. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000, 29:228-251.
191. Glucocorticoid Induced Osteoporosis: Guidelines for Prevention and Treatment. Bone and Tooth Society of Great Britain 2002, Bone and Tooth Society of Great Britain, The Lavenham Press Ltd., Sudbury, Suffolk, England.
192. Lane N., Goldring S., Stewart J., Morris S. Biochemical markers of bone turnover in glucocorticoid treated patients are altered by calcium supplementation: Preliminary results from the ACTIVATE trial. Arthritis Rheum 2003, 48:S498.
193. Sambrook P.N. Corticosteroid osteoporosis: Practical implications of recent trials. J Bone Miner Res 2000, 15:1645-1649.
194. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., Cooper S.M. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996, 125:961-968.
195. Wallach S., Cohen S., Reid D.M., Hughes R.A., Hosking D.J., Laan R.F., Doherty S.M., Maricic M., Rosen C., Brown J., Barton I., Chines A.A. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285.
196. Adachi R., Saag K., Emkey R., Cividino A., Brown J., Goemaere S., Dumortier T., Daifotis A., Czachur M. Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids. Arthritis Rheum 2001, 44:202-211.
197. Reid D.M., Hughes R., Laan R.F. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 2000, 15:1006-1013.
198. Sambrook P., Birmingham J., Kelly P., Kempler S., Nouven T., Stat M., et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993, 328:1747-1752.
199. Dykman T., Haralson K., Gluck O., Murphy W., Teitelbaum S., Hahn T., Hahn B. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984, 27:1336-1343.
200. Braun J.J., Birkenhager-Frenkel D.H., Rietvoeld A.H., Juttmann J.R., Visser T.J., Birkenhager J.C. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; A double blind controlled study. Clin Endocrinol 1983, 18:265-273.
201. Reginster J.Y., Kuntz D., Verdickt W., Wouters M., Guillevin L., Menkes C.-J., Nielsen K. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999, 9:75-81.
202. Bijlsma J.W.J., Raymakers J.A., Mosch C., Hoekstra A., Derksen R.H.W.M., Baart de la Faille H., Duursma S.A. Effect of oral calcium and vitamin D on glucocorticoidinduced osteopenia. Clin Exp Rheumatol 1988, 6:113-119.
203. Richy F., Ethgen O., Bruyere O., Reginster J.Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroidinduced osteoporosis: A meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004, 15:301-310.
204. F. Richy, E. Schacht, O. Bruyere, O. Ethgen, M. Gourlay, J. Y. Reginster: Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcif Tissue Int 76, 176-186.
205. de Nijs R.N., Jacobs J.W., Algra A., Lems W.F., Bijlsma J.W. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: A review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004, 15:589-602.
206. Ringe J., Coster A., Meng T., Schacht E., Umbach R. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/ calcium versus vitamin D/calcium. Calcif Tissue Int 1999, 65:337-340.
207. Ringe J., Dorst A., Faber H., Schacht E., Rahlfs V. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004, 24:63-70.
208. van Everdingen A.A., Siewertsz van Reesema D.R., Jacobs J.W., Bijlsma J.W. Low-dose glucocorticoids in early rheumatoid arthritis: Discordant effects on bone mineral density and fractures?. Clin Exp Rheumatol 2003, 21:155-160.
209. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996, 39:1791-1801. American College of Rheumatology Task Force on Osteoporosis Guidelines.
210. Geusens P., de Nijs R.N.J., Lems W.F., Laan R.F., Struijs A., Van Staa T.P., Bijlsma J.W. Prevention of glucocorticoid osteoporosis: A consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004, 63:324-325.
211. Devogelaer J.P., Goemaere S., Boonen S., Body J.J., Kaufman J.M., Reginster J.Y., Rozenberg S., Boutsen Y. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: A consensus document of the Belgian Bone Club. Osteoporos Int 2006, 17:8-19.
212. Van Staa T., Eastell R., Barton I.P., Rizzoli R., Javaid M.K., Cooper C. The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids. J Bone Miner Res 2003, 18:S66.
213. Eastell R., Barton I., Hannon R., Chines A., Garnero P., Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051-1056.
214. Angeli A., Guglielmi G., Dovio A., Capelli G., de Feo D., Giannini S., Giorgino R., Moro L., Giustina A. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone 2006, 39:253-259.
215. De Vries F., Bracke M., Leufkens H.G., Lammers J.W., Cooper C., Van Staa T.P. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007, 56:208-214.
216. Adachi J.D., Roux C., Pitt P.I., Cooper C., Moniz C., Dequeker J., Ionnidis G., Cawley M.I., Jenkins E.A., Walker-Bone K.E., Pack S., Stephenson G.F., Laan R.F., Brown J., Geusens P. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 2000, 27:2424-2431.
217. Reid D., Cohen C., Pack S., Chines A., Ethgen D. Risedronate reduces the incidence of vertebral fractures in patients on chronic corticosteroid therapy. Arthritis Rheum 1998, 41:S136.
218. Roux C., Oriente P., Laan R., Hughes R.A., Ittner J., Goemaere S., Di Munno O., Pouilles J.M., Horlait S., Cortet B. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998, 83:1128-1133.
219. Loddenkemper K., Grauer A., Burmester G.R., Buttgereit F. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases. Clin Exp Rheumatol 2003, 21:19-26.
220. Sebaldt R.J., Ioannidis G., Adachi J.D., Bensen W.G., Bianchi F., Cividino A., Gordon M., Kaminska E., Scocchia T., Petrie A., Stephenson G.F., Goldsmith C.H. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. J Rheumatol 1999, 26:1545-1549.
221. Pitt P., Todd P., Webber D., Pack S., Moniz C. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 1998, 53:351-356.
222. Geusens P., Dequeker J., Vanhoof J., Stalmans R., Boonen S., Joly J., Nijs J., Raus J. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 1998, 57:724-727.
223. Wolfhagen F.H., vanBuuren H.R., denOuden J.W., Hop W.C.J., van Leeuwen J.P.T.M., Schalm S.W., Pols H.A.P. Cyclic etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. J Hepatol 1997, 26:325-330.
224. Adachi J.D., Bensen W.G., Brown J., Hanley D., et al. Intermittent etidronate therapy to prevent corticosteroidinduced osteoporosis. N Engl J Med 1997, 337:382-387.
225. Struys A., Snelder A.A., Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995, 99:235-242.
226. Diamond T., McGuigan L., Barbagallo S., Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid- induced bone loss in postmenopausal women. Am J Med 1995, 98:459-463.
227. Skingle S.J., Crisp A.J. Increased bone density in patients on steroids with etidronate. Lancet 1994, 344:543.
228. Mulder H., Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994, 33:348-350.
229. Adachi J.D., Cranney A., Goldsmith C.H., Bensen W.G., Bianchi F., Cividino A., Craig G.L., Kaminska E., Sebaldt R.J., Papaioannou A., Boratto M., Gordon M., Steele M. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994, 21:1922-1926.
230. Gonnelli S., Rottoli P., Cepollaro C., Pondrelli C., Cappiello V., Vagliasindi M., Gennari C. Prevention of corticosteroidinduced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997, 6:382-385.
231. Jenkins E.A., Walker-Bone K.E., Wood A., McCrae F.C., Cooper C., Cawley M.I.D. The prevention of corticosteroid- induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999, 28:152-156.
232. Riggs L., Melton L. Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002, 17:11-14.
233. Sambrook P. Once weekly alendronate. Drugs Today (Barc) 2003, 39:339-346.
234. Blumel J., Castelo-Branco C., de la Cuadra G., Maciver L., Moreno M., Haya J. Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: Preliminary study on the effects in bone turnover markers and incidence of side effects. J Obstet Gynaecol 2003, 23:278-281.
235. Lanza F., Sahba B., Schwarts H., Winograd S., Torosis J., Quan H., Reyes R., Musliner T., Daifotis A., Leung A. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: A placebo-controlled endoscopy study. Am J Gastroenterol 2002, 97:58-64.
236. Greenspan S., Field-Munves E., Tonino R.P., Smith M., Petruschke R., Wang L., Yates J., de Papp A., Palmisano J. Tolerability of once-weekly alendronate in patients with osteoporosis: A randomized, double-blind, placebo-controlled study. Mayo Clinic Proc 2002, 77:1044-1052.
237. Schnitzer T., Bone H., Crepaldi G., Adami S., McClung M.R., Kiel D., Felsenberg D., Recker R., Tonino R., Roux C., Pinchera A., Foldes A., Greenspan S., Levine M., Emkey R., Santora A., Kaur A., Thompson D., Yates J., Orloff J. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 2000, 12:1-12.
238. Bone H.G., Hosking D., Devogelaer J.-P., Tucci J.R., Emkey R.D., Tonino R.P., Rodriguez-Portales J.A., Downs R.W., Gupta J., Santora A.C., Liberman U.A. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
239. Donahue J.G., Chan K.A., Andrade S.E., Beck A., Boles M., Buist D.S., Carey V.J., Chandler J.M., Chase G.A., Ettinger B., Fishman P., Goodman M., Guess H.A., Gurwitz J.H., LaCroix A.Z., Levin T.R., Platt R. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002, 162:936-942.
240. Boutsen Y., Jamart J., Esselinckx W., Stoffel M., Devogelaer J.-P. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial. Calcif Tissue Int 1997, 61:266-271.
241. Boutsen Y., Jamart J., Esselnickx W., Devogelaer J.P. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001, 16:104-112.
242. Gallacher S.J., Fenner J.A.K., Anderson K., Bryden F.M., Banham S.W., Logue F.C., Cowan R.A., Boyle I.T. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: An open pilot study. Thorax 1992, 47:932-936.
243. Valkema R., Vismans F.-J.E., Papapoulos S.E., Pauwels E.K.J., Bijvoet O.L.M. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989, 5:183-192.
244. Reid I.R., King A.R., Alexander C.J., Ibbertson H.K. Prevention of steroid-induced osteoporosis with (3-amino-1hydroxypropylidene)- 1, 1-bisphosphonate (APD). Lancet 1988, 1:143-146.
245. Lyritis G.P., Tsakalabos S., Magiasis B., et al. Analgesic effect of salmon calcitonin on osteoporotic vertebral fractures. Double-blind, placebo-controlled study. Calcif Tissue Int 1991, 49:369-372.
246. Lyritis G.P., Paspati I., Karachalios T., Ioakimidis D., Skarantavos G., Lyritis P.G. Pain relief from nasal salmon calcitonin in osteoporositic vertebral crush fractures. A double blind, placebo controlled clinical study. Acta Orthop Scand Suppl 1997, 275:112-114.
247. Pun K.K., Chan L.W.L. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Therapeutics 1989, 11:205-209.
248. Gangji V., Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999, 18:266-267.
249. Armingeat T., Brondino R., Pham T., Legre V., Lafforgue P. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: A randomized double-blind controlled study. Osteoporos Int 2006, 17:1659-1665.
250. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., Widmer A., Devogelaer J.-P., Kaufman J.-M., Jaeger P., Body J.-J., Brandi M.L., Broell J., Di Micco R., Genazzani A.R., Felsenberg D., Happ J., Hooper M.J., Ittner J., Leb G., Mallmin H., Murray T., Ortolani S., Rubinacci A., Sääf M., Samsioe G., Verbruggen L., Meunier P.J. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653-661.
251. Bauss F., Russell R. Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing. Osteoporos Int 2004, 15(6):423-433.
252. Ringe J.D., Dorst A., Faber H., Ibach K., Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. Osteoporos Int 2003, 14:801-807.
253. Ringe J.D., Dorst A., Faber H., Ibach K., Preuss J. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2003, 42:743-749.
254. Emkey R., Delmas P.D., Goemaere S., Liberman U.A., Poubelle P.E., Daifotis A.G., Verbruggen N., Lombardi A., Czachur M. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid- treated patients: A retrospective, observational study. Arthritis Rheum 2003, 48:1102-1108.
255. Adachi J.D., Bensen W.G., Bell M.J., Bianchi F.A., Cividino A.A., Craig G.L., Sturtridge W.C., Sebaldt R.J., Steele M., Gordon M., Themeles E., Tugwell P., Roberts R., Gent M. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997, 36:255-257.
256. Montemurro L., Schiraldi G., Fraioli P., Tosi G., Riboldi A., Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991, 49:71-76.
257. Healey J.H., Paget S.A., Williams-Russo P., Szatrowski T.P., Schneider R., Spiera H., Mitnick H., Ales K., Schwartzberg P. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996, 58:73-80.
258. Kotaniemi A., Piirainen H., Paimela L., Leirisalo-Repo M., Uoti-Reilama K., Lahdentausta P., Ruotsalainen P., Kataja M., Vaisanen E., Kurki P. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy?. J Rheumatol 1996, 23:1875-1879.
259. Luengo M., Pons F., Martinez de Osaba M.J., Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study. Thorax 1994, 49:1099.
260. Ringe J.-D., Welzel D. Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis. Eur J Clin Pharmacol 1987, 33:35-39.
261. Cranney A., Welch V., Adachi J., Homik J., Shea B., Suarez-Almazor M.E., Tugwell P., Wells G. Calcitonin for preventing and treating corticosteroid induced osteoporosis [Review]. Cochrane Collaboration 2005, 11-I31. The Cochrane Library.
262. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 288:321-333. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women.
263. Hall G.M., Daniels M., Doyle D.V., Spector T.D. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994, 37:1499-1505.
264. Hall G., Spector T., Delmas P. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis Rheum 1995, 38:902-906.
265. Lukert B.P., Johnson B.E., Robinson R.G. Estrogen and progesterone replacement therapy reduces glucocorticoidinduced bone loss. J Bone Miner Res 1992, 7:1063-1069.
266. Sambrook P., Birmingham J., Champion D., Kelly P., Kempler S., Freund J., Eisman J. Postmenopausal bone loss in rheumatoid arthritis: Effect of estrogens and androgens. J Rheumatol 1992, 19:357-361.
267. Tracz M.J., Sideras K., Bolona E.R., Haddad R.M., Kennedy C.C., Uraga M.V., Caples S.M., Erwin P.J., Montori V.M. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006, 91:2011-2016.
268. Wimalawansa S., Simmons D. Prevention of corticosteroid- induced bone loss with alendronate. Proc Soc Exp Biol Med 1998, 217:162-167.
269. Rhoden E., Morgentaler A. Medical progress: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482-492.
270. Greenspan S., Emkey R., Bone H., Weiss S., Bell N.H., Downs R.W., McKeever J.C., Miller S.S., Davidson M., Bolognese M.A., Mulloy A.L., Heyden N., Wu M., Kaur A., Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 137:875-883.
271. Fentiman I.S., Saad Z., Caleffi M., Chaudary M.A., Fogelman I. Tamoxifen protects against steroid-induced bone loss. Eur J Cancer 1992, 28:684-685.
272. Adams J.S., Song C.F., Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 1999, 130:658-660.
273. Adams J.S., Wahl T.O., Lukert B.P. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981, 30:217-221.
274. Shiraki M., Shiraki Y., Aoki C., Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000, 15:515-521.
275. Koshihara Y., Hoshi K., Okawara R., Ishibashi H., Yamamoto S. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol 2003, 176:339-348.
276. Yonemura K., Kimura M., Miyaji T., Hishida A. Shortterm effect of vitamin K administration on prednisoloneinduced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int 2000, 66:123-128.
277. Sasaki N., Kusano E., Takahashi H., Ando Y., Yano K., Tsuda E., Asano Y. Vitamin K2 inhibits glucocorticoidinduced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 2005, 23:41-47.
278. Sasaki N., Kusano E., Ando Y., Yano K., Tsuda E., Yasushi A. Glucocorticoid decreases circulating osteoprotegerin (OPG): Possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 2001, 16:479-482.
279. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., Kaufman J.M., Clancy A.D., Gaich G.A. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
280. Neer R., Arnaud C., Zanchetta J., Prince R., Gaich G., Reginster J., Hodsman A., Eriksen E., Ish-Shalom S., Genant H., Wang O., Mitlak B. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
281. Lane N., Sanchez S., Modin G., Genant H.K., Pierini E., Arnaud C. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
282. Oxlund H., Ortoft G., Thomsen J.S., Danielsen C.C., Ejersted C., Andreassen T.T. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006, 39:244-252.
283. Rehman Q., Lang T., Arnaud C., Modin G., Lane N. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003, 14:77-81.
284. Simonelli C., Killeen K., Mehle S., Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clinic Proc 2002, 77:334-338.
285. Solomon D.H., Kuntz K.K. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis?. Arthritis Rheum 2000, 43:1967-1975.
286. Buckley L.M., Hillner B.E. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 2003, 30:132-138.
287. van Staa T.P., Geusens P., Zhang B., Leufkens H.G., Boonen A., Cooper C. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford) 2007, 46:460-466.
288. Curtis J.R., Westfall A.O., Allison J.J., Freeman A., Saag K.G. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006, 17:1268-1274.
289. Walther F., Fusch C., Radke M., Beckert S., Findeisen A. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr 2006, 43:42-51.
290. Stark L.J., Davis A.M., Janicke D.M., Mackner L.M., Hommel K.A., Bean J.A., Lovell D., Heubi J.E., Kalkwarf H.J. A randomized clinical trial of dietary calcium to improve bone accretion in children with juvenile rheumatoid arthritis. J Pediatr 2006, 148:501-507.
291. Winzenberg T.M., Shaw K., Fryer J., Jones G. Calcium supplementation for improving bone mineral density in children. Cochrane Database Syst Rev 2006, CD005119.
292. Noguera A., Ros J.B., Pavia C., Alcover E., Valls C., Villaronga M., Gonzalez E. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003, 16:529-536.
293. Brown J.J., Zacharin M.R. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 2005, 41:580-582.
294. Nishioka T., Kurayama H., Yasuda T., Udagawa J., Matsumura C., Niimi H. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatr 1991, 118:703-707.
295. Bachrach L.K. Assessing bone health in children: Who to test and what does it mean?. Pediatr Endocrinol Rev 2005, 2(Suppl. 3):332-336.
296. Sanchez M.M., Gilsanz V. Pediatric DXA bone measurements. Pediatr Endocrinol Rev 2005, 2(Suppl. 3):337-341.
297. Brown J.J., Zacharin M.R. Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 2005, 41:553-557.